CEO Mike Rice commented, "We fully expect to participate in the forecasted growth of the CGT industry over the next several years. Sustained catalysts that we expect to drive BioLife growth due to a significant increase in the number of manufactured doses include: approvals of new cell and gene therapies, additional approvals of commercial CGT in new geographies, additional approvals of CGT in new indications, migration of commercial therapies to first or second-line treatment, an eventual transition to allogeneic therapies. We remain confident that we will achieve our Q4 2024 run rate aspirational financial goals of $250M in revenue, 50 points of adjusted gross margin and 30 points of adjusted EBITDA."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BLFS:
